Zadorab DSR Capsule 10s

Uses of Zadorab DSR Capsule 10s

Rabeprazole sodium and domperidone uses include various gastric conditions which leads to gastric reflux or other symptoms like heartburn, gastric ulcers, difficulty swallowing, and persistent cough.

Side Effects of Zadorab DSR Capsule 10s

Increased risk of Clostridium difficile-associated diarrhoea (CDAD) and osteoporosis-related fractures. Headache, rash, pruritus, dizziness, fatigue, cough, back or abdominal pain, arthralgia and myalgia, urticaria, dry mouth, photosensitivity, bullous eruption, fever, angioedema, bronchospasm, somnolence, aggression and vertigo, insomnia, reversible confusional states, depression, agitation, hallucination. Increased liver enzyme, hepatitis, jaundice, hepatic encephalopathy. Rarely, candidiasis, paraesthesia, alopecia, muscular weakness, angina, tachycardia, bradycardia, blurred vision, alopecia, stomatitis, increased sweating, taste disturbances, peripheral oedema, malaise, hyponatraemia, hypomagnesaemia, blood disorders (e.g. agranulocytosis, leucopenia and thrombocytopenia), gynaecomastia, impotence and interstitial nephritis. Potentially Fatal: Anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Drug Interactions

May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate. Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.

Contraindications

Concomitant use w/ rilpivirine and atazanavir.

Mechanism of Action

Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell. Onset: W/in 1 hr. Duration: 24 hr. Absorption: Rapidly absorbed. Oral bioavailability: Approx 52%. Time to peak plasma concentration: Approx 3.5 hr. Distribution: Plasma protein binding: Approx 97%. Metabolism: Extensive hepatic metabolism mainly by CYP2C19 and CYP3A4 isoenzymes. Excretion: Mainly via urine (approx 90%), the remainder via faeces. Plasma half-life: Approx 1-2 hr.

Special Precautions

Gastric malignancy should be ruled out. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.